CA2386865A1 - Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28 - Google Patents

Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28 Download PDF

Info

Publication number
CA2386865A1
CA2386865A1 CA002386865A CA2386865A CA2386865A1 CA 2386865 A1 CA2386865 A1 CA 2386865A1 CA 002386865 A CA002386865 A CA 002386865A CA 2386865 A CA2386865 A CA 2386865A CA 2386865 A1 CA2386865 A1 CA 2386865A1
Authority
CA
Canada
Prior art keywords
seq
sgp28
amino acids
antibody
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002386865A
Other languages
English (en)
Other versions
CA2386865C (fr
Inventor
Rene S. Hubert
Arthur B. Raitano
Daniel E. H. Afar
Steve Chappell Mitchell
Mary Faris
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys, Inc.
Rene S. Hubert
Arthur B. Raitano
Daniel E. H. Afar
Steve Chappell Mitchell
Mary Faris
Aya Jakobovits
Urogenesys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys, Inc., Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Steve Chappell Mitchell, Mary Faris, Aya Jakobovits, Urogenesys, Inc. filed Critical Agensys, Inc.
Publication of CA2386865A1 publication Critical patent/CA2386865A1/fr
Application granted granted Critical
Publication of CA2386865C publication Critical patent/CA2386865C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)

Abstract

La présente invention concerne des procédés et compositions destinés au diagnostic et au traitement du cancer de la prostate. On utilise à cet effet des polynucléotides correspondant au gène SGP-28 humain, des protéines codées par le gène SGP-28 ou certains de leurs fragments, et des anticorps spécifiquement capables de reconnaître des protéines du SGP-28 ou de s'y lier.
CA2386865A 1999-10-28 2000-10-27 Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28 Expired - Fee Related CA2386865C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16261099P 1999-10-28 1999-10-28
US60/162,610 1999-10-28
PCT/US2000/029607 WO2001031343A2 (fr) 1999-10-28 2000-10-27 Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28

Publications (2)

Publication Number Publication Date
CA2386865A1 true CA2386865A1 (fr) 2001-05-03
CA2386865C CA2386865C (fr) 2012-05-22

Family

ID=22586387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2386865A Expired - Fee Related CA2386865C (fr) 1999-10-28 2000-10-27 Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28

Country Status (9)

Country Link
EP (1) EP1228373B1 (fr)
JP (2) JP3779926B2 (fr)
AT (1) ATE291738T1 (fr)
AU (1) AU781223B2 (fr)
CA (1) CA2386865C (fr)
DE (1) DE60018964T2 (fr)
ES (1) ES2240192T3 (fr)
IL (3) IL149045A0 (fr)
WO (1) WO2001031343A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110006A1 (fr) * 2007-03-12 2008-09-18 Miraculins Inc. Biomarqueurs du cancer de la prostate et utilisations de ceux-ci

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835822B1 (en) 1999-10-28 2004-12-28 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
EP1513865A4 (fr) * 2002-05-28 2006-05-03 Univ Minnesota Utilisation de polyppetides crisp comme contaceptifs et inhibiteurs de capacitation du sperme
US20110144673A1 (en) 2009-12-11 2011-06-16 Fox Hollow Technologies, Inc. Material removal device having improved material capture efficiency and methods of use
CN102914658A (zh) * 2012-10-24 2013-02-06 高维强 Crisp3蛋白在前列腺癌诊断和治疗中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110006A1 (fr) * 2007-03-12 2008-09-18 Miraculins Inc. Biomarqueurs du cancer de la prostate et utilisations de ceux-ci

Also Published As

Publication number Publication date
WO2001031343A2 (fr) 2001-05-03
AU781223B2 (en) 2005-05-12
DE60018964D1 (de) 2005-04-28
JP2006187290A (ja) 2006-07-20
CA2386865C (fr) 2012-05-22
AU1237201A (en) 2001-05-08
WO2001031343A3 (fr) 2002-01-31
IL207012A (en) 2013-05-30
DE60018964T2 (de) 2006-01-12
JP4325943B2 (ja) 2009-09-02
ES2240192T3 (es) 2005-10-16
EP1228373B1 (fr) 2005-03-23
ATE291738T1 (de) 2005-04-15
JP3779926B2 (ja) 2006-05-31
IL149045A0 (en) 2002-11-10
JP2003512825A (ja) 2003-04-08
IL149045A (en) 2010-11-30
IL207012A0 (en) 2011-08-01
EP1228373A2 (fr) 2002-08-07

Similar Documents

Publication Publication Date Title
CA2386858A1 (fr) 36p6d5: antigene tumoral secrete
CN105121473B (zh) α-突触核蛋白抗体及其用途
RU2013113439A (ru) Идентификация опухолеассоциированных антигенов для диагностики и терапии
EA030777B1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
CA2633413A1 (fr) Compositions et procedes destines au diagnostic et au traitement de tumeurs
CA2280930A1 (fr) Proteines-marqueurs pour le cancer du poumon et utilisation de ces dernieres
HRP931147A2 (hr) Metoda za rano otkrivanje, otkrivanje ozbiljnosti i za popratnu procijenu tijeka sepse pri samom tretmanu iste i sredstva za provođenje spomenute metode
CA2879304C (fr) Procede de detection de cancer
KR102056137B1 (ko) 암의 검출 방법
KR20120041175A (ko) 미량 존재하는 인간 혈장 단백질 바이오마커의 신규 패널을 이용한 간성 섬유증의 임상적 진단
RU2004125165A (ru) Новый лиганд рецептора цитокина zcytor17
CA2380550A1 (fr) Antigene transmembranaire lectine du type c exprime dans le cancer humain de la prostate et ses utilisations
RU2693006C2 (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
KR20110000548A (ko) 신장암의 진단 또는 검출을 위한 조성물 및 방법
AU763162B2 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
CA2386865A1 (fr) Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28
KR101777259B1 (ko) En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN116693681B (zh) 抗幽门螺杆菌细胞毒素相关蛋白a的单克隆抗体及其应用
KR102450481B1 (ko) 돼지열병 바이러스 특이적인 항체 및 이의 용도
EP1187853B1 (fr) Nouvelles utilisations diagnostiques d'anticorps diriges contre l'acetylcholinesterase ou ses peptides c-terminaux
ES2376167T3 (es) Inmunoensayos para la determinación espec�?fica de isoformas de scca.
CN106674347B (zh) 一种新型耳抑素抗体
KR20190083110A (ko) 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트
EP2045328B1 (fr) Sequences peptidiques et nucleotidiques d'anisakis spp. et leurs applications
KR20140041435A (ko) 항il28b 항체 및 이것을 사용한 il28b의 측정 방법

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151027